Research graph
References from Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab. Local targets link to admitted publications; unresolved targets remain external evidence.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
10.1016/s1474-4422(22)00143-0 · 2022 · External reference
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
10.1177/13524585211003020 · 2021 · External reference
Pharmacokinetics and pharmacodynamics of natalizumab 6-Week dosing vs continued 4-Week dosing for relapsing-remitting multiple sclerosis
10.1212/nxi.0000000000200321 · 2024 · External reference
Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
10.1007/s13760-024-02480-6 · 2024 · External reference
Extended interval dosing of natalizumab in multiple sclerosis
10.1136/jnnp-2015-312940 · 2016 · External reference
Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic
10.1016/j.jns.2021.117622 · 2021 · External reference
The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms
10.1212/wnl.0000000000008357 · 2019 · External reference
End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
10.1016/j.msard.2020.102020 · 2020 · External reference
Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker
10.1212/nxi.0000000000000706 · 2020 · External reference
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
10.1212/nxi.0000000000000678 · 2020 · External reference
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study
10.1016/j.jns.2020.116880 · 2020 · External reference
Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules
10.1016/j.msard.2024.106146 · 2024 · External reference
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
10.1177/13524585241293940 · 2024 · External reference
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
10.1212/nxi.0000000000000271 · 2016 · External reference
Effect of natalizumab on sNfL and sGFAP levels in multiple sclerosis patients
10.3390/ijms252313153 · 2024 · External reference
Identifying the start of multiple sclerosis injury: a serial DTI study
10.1111/jon.12082 · 2014 · External reference
Measuring brain tissue integrity during 4 years using diffusion tensor imaging
10.3174/ajnr.a4946 · 2017 · External reference
[digital medicine in neurological research-between hype and evidence]
10.1007/s00115-023-01581-6 · 2024 · External reference
Evidence from clinicalTrials.gov on the growth of digital health technologies in neurology trials
10.1038/s41746-023-00767-1 · 2023 · External reference
Digital activity markers in chronic inflammatory demyelinating polyneuropathy
10.1002/acn3.70137 · 2025 · External reference
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
10.1007/s00415-016-8334-6 · 2017 · External reference
Modeling multiple sclerosis using Mobile and wearable sensor data
10.1038/s41746-024-01025-8 · 2024 · External reference
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
10.1016/s1474-4422(17)30470-2 · 2018 · External reference
The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment
10.1177/135245859900500409 · 1999 · External reference
MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation
10.1016/j.neuroimage.2019.116137 · 2019 · External reference
Denoising of diffusion MRI using random matrix theory
10.1016/j.neuroimage.2016.08.016 · 2016 · External reference
Gibbs-ringing artifact removal based on local subvoxel-shifts
10.1002/mrm.26054 · 2016 · External reference
An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging
10.1016/j.neuroimage.2015.10.019 · 2016 · External reference
How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging
10.1016/s1053-8119(03)00336-7 · 2003 · External reference
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data
10.1016/j.neuroimage.2006.02.024 · 2006 · External reference
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
10.1016/s1474-4422(22)00009-6 · 2022 · External reference
Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis
10.1002/ana.27096 · 2025 · External reference
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
10.1016/j.cca.2025.120447 · 2025 · External reference
Annual 12-Week dosing gap of natalizumab: clinical efficacy, blood biomarkers, and CSF cell composition
10.1002/acn3.70207 · 2026 · External reference
The physical activity guidelines for Americans
10.1001/jama.2018.14854 · 2018 · External reference
2024 adult compendium of physical activities: a third update of the energy costs of human activities
10.1016/j.jshs.2023.10.010 · 2024 · External reference
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
10.1136/jnnp-2024-335673 · 2025 · External reference
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
2024 · External reference
A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion-weighted magnetic resonance imaging
10.1016/j.mri.2023.09.010 · 2023 · External reference
White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis
10.3174/ajnr.a4690 · 2016 · External reference
Microstructure abnormalities of diffusion tensor imaging measures in first-episode, treatment-naïve adolescents with major depressive disorder: an integrated AFQ and TBSS study
2025 · External reference
No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies
2025 · External reference
Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity
10.1016/j.msard.2023.105104 · 2023 · External reference
Long-term adherence to a wearable for continuous behavioural activity measuring in the SafeHeart implantable cardioverter defibrillator population
10.1093/ehjdh/ztae055 · 2024 · External reference
Assessment of hypertension control among adults participating in a Mobile technology blood pressure self-Management program
10.1001/jamanetworkopen.2021.27008 · 2021 · External reference
The physical activity guidelines for Americans
10.1001/jama.2018.14854 · ExternalCitation · doi-reference
Assessment of hypertension control among adults participating in a Mobile technology blood pressure self-Management program
10.1001/jamanetworkopen.2021.27008 · ExternalCitation · doi-reference
Digital activity markers in chronic inflammatory demyelinating polyneuropathy
10.1002/acn3.70137 · ExternalCitation · doi-reference
Annual 12-Week dosing gap of natalizumab: clinical efficacy, blood biomarkers, and CSF cell composition
10.1002/acn3.70207 · ExternalCitation · doi-reference
Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis
10.1002/ana.27096 · ExternalCitation · doi-reference
Gibbs-ringing artifact removal based on local subvoxel-shifts
10.1002/mrm.26054 · ExternalCitation · doi-reference
[digital medicine in neurological research-between hype and evidence]
10.1007/s00115-023-01581-6 · ExternalCitation · doi-reference
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
10.1007/s00415-016-8334-6 · ExternalCitation · doi-reference
Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
10.1007/s13760-024-02480-6 · ExternalCitation · doi-reference
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
10.1016/j.cca.2025.120447 · ExternalCitation · doi-reference
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study
10.1016/j.jns.2020.116880 · ExternalCitation · doi-reference
Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic
10.1016/j.jns.2021.117622 · ExternalCitation · doi-reference
2024 adult compendium of physical activities: a third update of the energy costs of human activities
10.1016/j.jshs.2023.10.010 · ExternalCitation · doi-reference
A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion-weighted magnetic resonance imaging
10.1016/j.mri.2023.09.010 · ExternalCitation · doi-reference
End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
10.1016/j.msard.2020.102020 · ExternalCitation · doi-reference
Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity
10.1016/j.msard.2023.105104 · ExternalCitation · doi-reference
Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules
10.1016/j.msard.2024.106146 · ExternalCitation · doi-reference
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data
10.1016/j.neuroimage.2006.02.024 · ExternalCitation · doi-reference
An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging
10.1016/j.neuroimage.2015.10.019 · ExternalCitation · doi-reference
Denoising of diffusion MRI using random matrix theory
10.1016/j.neuroimage.2016.08.016 · ExternalCitation · doi-reference
MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation
10.1016/j.neuroimage.2019.116137 · ExternalCitation · doi-reference
How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging
10.1016/s1053-8119(03)00336-7 · ExternalCitation · doi-reference
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
10.1016/s1474-4422(17)30470-2 · ExternalCitation · doi-reference
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
10.1016/s1474-4422(22)00009-6 · ExternalCitation · doi-reference
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
10.1016/s1474-4422(22)00143-0 · ExternalCitation · doi-reference
Evidence from clinicalTrials.gov on the growth of digital health technologies in neurology trials
10.1038/s41746-023-00767-1 · ExternalCitation · doi-reference
Modeling multiple sclerosis using Mobile and wearable sensor data
10.1038/s41746-024-01025-8 · ExternalCitation · doi-reference
Long-term adherence to a wearable for continuous behavioural activity measuring in the SafeHeart implantable cardioverter defibrillator population
10.1093/ehjdh/ztae055 · ExternalCitation · doi-reference
Identifying the start of multiple sclerosis injury: a serial DTI study
10.1111/jon.12082 · ExternalCitation · doi-reference
Extended interval dosing of natalizumab in multiple sclerosis
10.1136/jnnp-2015-312940 · ExternalCitation · doi-reference
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
10.1136/jnnp-2024-335673 · ExternalCitation · doi-reference
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
10.1177/13524585211003020 · ExternalCitation · doi-reference
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
10.1177/13524585241293940 · ExternalCitation · doi-reference
The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment
10.1177/135245859900500409 · ExternalCitation · doi-reference
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
10.1212/nxi.0000000000000271 · ExternalCitation · doi-reference
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
10.1212/nxi.0000000000000678 · ExternalCitation · doi-reference
Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker
10.1212/nxi.0000000000000706 · ExternalCitation · doi-reference
Pharmacokinetics and pharmacodynamics of natalizumab 6-Week dosing vs continued 4-Week dosing for relapsing-remitting multiple sclerosis
10.1212/nxi.0000000000200321 · ExternalCitation · doi-reference
The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms
10.1212/wnl.0000000000008357 · ExternalCitation · doi-reference
White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis
10.3174/ajnr.a4690 · ExternalCitation · doi-reference
Measuring brain tissue integrity during 4 years using diffusion tensor imaging
10.3174/ajnr.a4946 · ExternalCitation · doi-reference
Effect of natalizumab on sNfL and sGFAP levels in multiple sclerosis patients
10.3390/ijms252313153 · ExternalCitation · doi-reference
